Monash-developed antibody may be first of a new class of antiplatelet

A new class of anti-platelet therapy has been developed by researchers from Monash University that provides selective blockade of thrombus formation while maintaining normal haemostasis. Researchers from the Australian Centre for Blood Diseases  have described how they engineered a novel single-chain antibody (scFv) that exclusively recognises and blocks the pathological form of the Von Willebrand Factor ...

Already a member?

Login to keep reading.

© 2021 the limbic